The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Sponsor:
Edison Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT01728064
First received: November 13, 2012
| Condition | Intervention | Phase |
|---|---|---|
|
Friedreich's Ataxia |
Drug: Placebo Drug: EPI-743 400 mg Drug: EPI-743 200 mg |
Phase 2 |
